Literature DB >> 8719237

Simulation for population analysis of Michaelis-Menten elimination kinetics.

Y Hashimoto1, T Koue, Y Otsuki, M Yasuhara, R Hori, K Inui.   

Abstract

A simulation study was conducted to compare the cost and performance of various models for population analysis of the steady state pharmacokinetic data arising from a one-compartment model with Michaelis-Menten elimination. The usual Michaelis-Menten model (MM) and its variants provide no estimate of the volume of distribution, and generally give poor estimates of the maximal elimination rate and the Michaelis-Menten constant. The exact solution to the Michaelis-Menten differential equation (TRUE) requires a precise analysis method designed for estimation of population pharmacokinetic parameters (the first-order conditional estimation method) and also considerable computational time to estimate population mean parameters accurately. The one-compartment model with dose-dependent clearance (DDCL), in conjunction with the first-order conditional estimation or Laplacian method, ran approximately 20-fold faster than TRUE and gave accurate population mean parameters for a drug having a long biological half-life relative to the dosing interval. These findings suggest that the well-known MM and its variants should be used carefully for the analysis of blood concentrations of a drug with Michaelis-Menten elimination kinetics, and that TRUE, in conjunction with a precise analysis method, should be considered for estimating population pharmacokinetic parameters. In addition, DDCL is a promising alternative to TRUE with respect to computation time, when the dosing interval is short relative to the biological half-life of a drug.

Entities:  

Mesh:

Year:  1995        PMID: 8719237     DOI: 10.1007/BF02354272

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

Review 1.  Population pharmacokinetics/dynamics.

Authors:  L B Sheiner; T M Ludden
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

2.  Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update.

Authors:  E Yukawa; S Higuchi; T Aoyama
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-07       Impact factor: 1.645

3.  Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients.

Authors:  J Grevel; B K Post; B D Kahan
Journal:  Clin Pharmacol Ther       Date:  1993-06       Impact factor: 6.875

4.  Simulation for the analysis of distorted pharmacodynamic data.

Authors:  Y Hashimoto; J Ozaki; T Koue; A Odani; M Yasuhara; R Hori
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

5.  Computation of the explicit solution to the Michaelis-Menten equation.

Authors:  S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

6.  On the solution to the Michaelis-Menten equation.

Authors:  S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

7.  Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients.

Authors:  Y Hashimoto; A Odani; Y Tanigawara; M Yasuhara; T Okuno; R Hori
Journal:  Biol Pharm Bull       Date:  1994-02       Impact factor: 2.233

8.  Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data.

Authors:  M J García; R Gavira; D Santos Buelga; A Dominguez-Gil
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

9.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
  9 in total
  2 in total

1.  Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.